GlassScriptPhysician profile
Hal A Lewis
NPI 1124554209
$137,854.10
in general payments reported to CMS, 2019-2025
27 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $305 · 2021: $601 · 2022: $4,065 · 2023: $33K · 2024: $46K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $12K · Consulting Fee: $7,350 · Food and Beverage: $6,626 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,925.00 |
| Travel and Lodging | $12,337.15 |
| Consulting Fee | $7,350.00 |
| Food and Beverage | $6,626.44 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74,741.59 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $49,791.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,466.84 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $932.05 | 2022-2025 | |
| Janssen Biotech, INC. | $845.21 | 2021-2025 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $524.15 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $445.95 | 2021-2025 | Libtayo, Dupixent |
| Incyte Corporation | $233.10 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $217.68 | 2022-2025 | Winlevi |
| Ucb, INC. | $209.97 | 2021-2025 | Bimzelx, Cimzia |
| Allergan, INC. | $203.59 | 2019-2022 | |
| Galderma Laboratories, L.P. | $194.96 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $181.06 | 2021-2025 | |
| Pfizer INC. | $166.61 | 2023-2025 | |
| Organon LLC | $116.16 | 2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $113.13 | 2023 | Xtrac |
| Dermavant Sciences, INC. | $103.43 | 2022-2024 | Vtama |
| Almirall LLC | $99.12 | 2022-2025 | Klisyri |
| Sanofi-Aventis U.S. LLC | $68.99 | 2023 | |
| Leo Pharma INC. | $64.18 | 2021-2024 | Adbry |
| Polynovo North America LLC | $25.37 | 2024 | Novosorb Btm |
| Revance Therapeutics, INC. | $23.34 | 2025 | Daxxify |
| Sientra, INC. | $20.45 | 2022 | |
| Journey Medical Corporation | $17.31 | 2023 | |
| Kci USA, INC. | $17.06 | 2022 | |
| Botanix Sb INC | $15.80 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $15.38 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.